|
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| Jul. 13 | BMO Capital Adjusts Price Target on Pfizer to $30 From $34, Maintains Outperform Rating | MT |
| Jul. 12 | Pfizer, Astellas Secure FDA Nod For Bladder Cancer Drug | MT |
| Market Cap | 138B 121B 112B 103B 195B 13,172B 199B 1,338B 524B 6,459B 517B 506B 22,376B | P/E 2026 * |
12.3x | P/E 2027 * | 12.7x |
|---|---|---|---|---|---|
| Enterprise Value | 187B 164B 152B 140B 265B 17,886B 270B 1,817B 711B 8,771B 702B 687B 30,383B | EV / Sales 2026 * |
3.03x | EV / Sales 2027 * | 3.05x |
| Free-Float |
59.06% | Yield 2026 * |
7.14% | Yield 2027 * | 7.21% |
Last Transcript: Pfizer Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Albert Bourla
CEO | Chief Executive Officer | 64 | 2018-12-31 |
David Denton
DFI | Director of Finance/CFO | 60 | 2022-05-01 |
| Chief Tech/Sci/R&D Officer | - | 2006-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Suzanne Johnson
BRD | Director/Board Member | 68 | 2007-08-31 |
Shantanu Narayen
BRD | Director/Board Member | 62 | 2013-09-26 |
Albert Bourla
CHM | Chairman | 64 | 2019-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.56% | -2.64% | +49.04% | +168.24% | 1,060B | |
| +0.31% | -2.00% | +64.29% | +63.06% | 619B | |
| -0.03% | -5.01% | +28.86% | +83.73% | 438B | |
| -1.75% | -2.91% | +28.78% | +24.35% | 333B | |
| +0.24% | -2.61% | +29.46% | +46.50% | 282B | |
| -1.75% | -12.77% | +20.67% | +23.05% | 267B | |
| +0.67% | -0.76% | -26.10% | -37.25% | 218B | |
| -0.81% | -3.66% | +22.07% | +59.72% | 196B | |
| +1.21% | +0.10% | +19.85% | +72.03% | 161B | |
| Average | -0.15% | -3.37% | +26.32% | +55.94% | 397.1B | |
| Weighted average by Cap. | -0.02% | -3.14% | +36.27% | +82.99% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 61.74B 54.25B 50.26B 46.26B 87.38B 5,904B 89.27B 600B 235B 2,895B 232B 227B 10,029B | 59.36B 52.16B 48.32B 44.48B 84.01B 5,676B 85.82B 577B 226B 2,783B 223B 218B 9,642B |
| Net income | 10.63B 9.34B 8.65B 7.96B 15.04B 1,016B 15.36B 103B 40.39B 498B 39.9B 39.03B 1,726B | 10.27B 9.02B 8.36B 7.69B 14.53B 982B 14.84B 99.73B 39.03B 481B 38.55B 37.71B 1,668B |
| Net Debt | 49.3B 43.31B 40.13B 36.94B 69.77B 4,714B 71.27B 479B 187B 2,312B 185B 181B 8,007B | 43.17B 37.93B 35.14B 32.34B 61.09B 4,128B 62.41B 419B 164B 2,024B 162B 159B 7,012B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
